Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Common-Size Balance Sheet: Assets 

Bristol-Myers Squibb Co., common-size consolidated balance sheet: assets

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Cash and cash equivalents 11.17 12.05 9.42 12.79 12.28
Marketable debt securities 0.55 0.86 0.13 2.73 1.08
Net trade receivables 9.73 9.33 8.42 7.30 6.09
Alliance, royalties, VAT and other 1.87 2.14 1.79 1.27 1.08
Receivables 11.61% 11.48% 10.21% 8.57% 7.17%
Inventories 2.76 2.80 2.42 1.92 1.75
Income taxes 3.55 4.13 3.66 2.55 1.52
Research and development 0.81 0.76 0.60 0.47 0.42
Contract assets 0.42 0.44 0.52 0.33 0.21
Equity investments 0.00 0.00 0.00 0.23 0.52
Restricted cash 0.00 0.06 0.15 0.13 0.08
Other 1.28 0.83 1.05 0.71 0.45
Other current assets 6.07% 6.21% 5.99% 4.42% 3.20%
Current assets 32.16% 33.39% 28.17% 30.43% 25.48%
Property, plant and equipment 7.71 6.98 6.46 5.53 4.97
Goodwill 23.45 22.25 21.84 18.76 17.34
Other intangible assets 25.17 28.45 37.04 38.90 44.94
Deferred income taxes 4.57 2.91 1.39 1.32 0.98
Marketable debt securities 0.35 0.38 0.00 0.00 0.37
Equity investments 1.87 1.79 2.26 2.48 3.44
Operating lease right-of-use assets 1.32 1.46 1.26 0.84 0.73
Inventories 1.69 0.95 0.50 0.83 0.91
Pension and postretirement 0.25 0.30 0.29 0.29 0.18
Research and development 0.36 0.43 0.51 0.23 0.17
Restricted cash 0.00 0.00 0.06 0.18 0.29
Receivables and convertible notes 0.49 0.46 0.00 0.00 0.00
Other 0.60 0.25 0.22 0.21 0.21
Other non-current assets 6.59% 5.64% 5.10% 5.06% 5.92%
Non-current assets 67.84% 66.61% 71.83% 69.57% 74.52%
Total assets 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co. current assets as a percentage of total assets increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.
Property, plant and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Bristol-Myers Squibb Co. property, plant and equipment as a percentage of total assets increased from 2022 to 2023 and from 2023 to 2024.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co. non-current assets as a percentage of total assets decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.